Circulation, Vol 90, 2519-2524, Copyright © 1994 by American Heart Association
EM Redmond, MN Cherian and RC Wetzel
BACKGROUND--Because of the marked difference in the incidence and severity
of cardiovascular diseases between men and premenopausal women, several
groups have studied the effect of sex steroids, particularly estrogen, on
vascular endothelial prostacyclin (PGI2) release. No previous studies have
addressed the effect of estrogen on endocardial endothelial cells (EECs),
which are involved in the modulation of the myocardium and potentially in
downstream pulmonary and systemic vascular tone. Furthermore, all previous
studies of estrogen effects on cultured endothelial cell function have used
cells grown under standard static cell culture conditions, thereby ignoring
the contribution of flow, the ubiquitous environmental endothelial
stimulus. METHODS AND RESULTS--The effect of 17 beta-estradiol pretreatment
(100 ng/mL, 72 hours) on cultured sheep EEC PGI2 release in response to
multiple physiologically relevant stimuli was studied. EECs were grown in
six-well plates (static conditions) or on microcarrier beads and perfused
at a constant flow with normoxic (PO2 = 150 mm Hg, PCO2 = 35 mm Hg) or
hypoxic (PO2 = 35 mm Hg, PCO2 = 35 mm Hg) Krebs solution. The stable
metabolite of PGI2, 6-keto-PGF1 alpha, was determined in samples from both
static and perfusion experiments by direct radioimmunoassay. 17
beta-Estradiol pretreatment did not alter basal or stimulated (arachidonic
acid, 1 mumol/L, 10 mumol/L; A23187, 10 mumol/L; and bradykinin, 1 mumol/L)
PGI2 release in static conditions. Untreated and acutely treated (100 ng/mL
added to perfusate) EECs responded to flow with a time-dependent increase
in PGI2 release that plateaued between 60 and 100 minutes. In contrast, 17
beta-estradiol-pretreated, perfused EECs did not increase PGI2 release over
time. During perfusion, acute hypoxia increased PGI2 release: 140 +/- 65
(normoxia) to 296 +/- 113 pg (hypoxia) 6-keto-PGF1 alpha/mg per minute. 17
beta-Estradiol inhibited hypoxia-induced PGI2 release: 296 +/- 113 pg
(untreated EECs, hypoxia) versus 159 +/- 60 pg (17 beta- estradiol
pretreated, hypoxia) 6-keto-PGF1 alpha/mg per minute. CONCLUSIONS--This
study demonstrates for the first time an inhibitory effect of 17
beta-estradiol on flow- and acute hypoxia-induced increase in PGI2 release
from perfused EECs in the absence of any effect on pharmacologically
stimulated PGI2 release from static cultures. These effects of 17
beta-estradiol may explain in part the well-recognized gender and estrogen
effects in cardiovascular diseases and highlight the importance of flow in
studies of endothelial cell function.
ARTICLES
17 beta-Estradiol inhibits flow- and acute hypoxia-induced prostacyclin release from perfused endocardial endothelial cells
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Md.
This article has been cited by other articles:
![]() |
D. L. Brutsaert Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity Physiol Rev, January 1, 2003; 83(1): 59 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Selzman, T. A. Whitehill, B. D. Shames, E. J. Pulido, B. C. Cain, and A. H. Harken The Biology of Estrogen-Mediated Repair of Cardiovascular Injury Ann. Thorac. Surg., March 1, 1998; 65(3): 868 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Redmond, P. A. Cahill, and J. V. Sitzmann Flow-Mediated Regulation of G-Protein Expression in Cocultured Vascular Smooth Muscle and Endothelial Cells Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 75 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Guetta and R. O. Cannon III Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women Circulation, May 15, 1996; 93(10): 1928 - 1937. [Full Text] |
||||
![]() |
K. J. Scheidegger, B. Cenni, D. Picard, and P. Delafontaine Estradiol Decreases IGF-1 and IGF-1 Receptor Expression in Rat Aortic Smooth Muscle Cells. MECHANISMS FOR ITS ATHEROPROTECTIVE EFFECTS J. Biol. Chem., December 1, 2000; 275(49): 38921 - 38928. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1994 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |